| Compare | Payout | Min deposit | Promo code | Win rate(%) | Welcome bonus | Rating | |
|---|---|---|---|---|---|---|---|
|
New  |
1 min. | 20 $ | LINKER | 60 % | 500 + FS | PLAY NOW | |
 |
60 min. | 20 $ | RUBYSKYE | 60 % | 500 + FS | PLAY NOW | |
 |
2 hr. | 20 $ | RUBYSKYE | 60 % | 500 + FS | PLAY NOW | |
|
Promo  |
60 min. | 40 $ | RUBYSKYE | 60 % | 500$ +150 FS | PLAY NOW | |
 |
60 min. | 20 $ | RUBYSKYE | 60 % | 500 + FS | PLAY NOW |
SYK designs, manufactures, and markets medical products, including implants and surgical equipment. Stryker is a leading player in the medical devices sector and is looking to keep growing. While the company did recently offload its spinal implants business, it did acquire seven other companies in 2024 and is eyeing more in 2025. Similarly, the trend of people having more surgical procedures is helping the company grow.
Financially, SYK just announced earnings for the fourth quarter of fiscal 2024. The company experienced more than 10% organic sales growth. In terms of earnings, SYK’s adjusted per-share earnings were $4.01 for the quarter and $12.19 for the entire year. In terms of growth, those figures are 16% and 15% higher than their previous periods, respectively. The company expects up to 9% organic sales growth next year and adjusted EPS of up to $13.70 as it looks to strategically grow.
It’s no wonder SYK shares are up almost 19% in the last six months – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.
Institutional volumes reveal plenty. Over the last year, SYK has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in SYK shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Stryker.
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, SYK has had solid sales and earnings growth:
Source: FactSet
Plus, EPS is estimated to ramp higher this year by +10.7%.
Now it makes sense why the stock has been powering to new heights. SYK has a track record of strong financial performance.
Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.
Stryker has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when SYK was a top pick…rising higher:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
